Nomura expects Indian markets to trade in the range of 20-22x one-year forward earnings, assuming risk premia remain low.
The selling pressure on the counter came after the company's subsidiary, Optival Health Solutions, received a suspension order for a drug license of a store situated in Karnataka
Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.